A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
The clinical trial, sponsored by Southwest Hospital in China, focuses on the safety and dosage of CD19-targeted CAR T cells for treating relapsed or refractory B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma. Given the increasing demand for innovative therapies in hematological cancers, this trial positions itself in a competitive landscape dominated by established CAR T therapies like Kymriah and Yescarta. The successful demonstration of safety and efficacy could lead to significant market opportunities, especially in regions with high unmet medical needs. The trial's ongoing recruitment phase indicates potential for timely data readouts, which may attract interest from larger biopharma companies for partnerships or acquisitions.
Indication: Leukemia
Modality: protein therapy
Target: CD19 positive malignant B-cell derived leukemia and lymphoma
Sponsor: Southwest Hospital, China
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 positive malignant B-cell derived leukemia and lymphoma
View original source fields
Condition raw: Leukemia, Lymphoma
Condition normalized: Leukemia, Lymphoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19 positive malignant B-cell derived leukemia and lymphoma
Target normalized: CD19 positive malignant B-cell derived leukemia and lymphoma